Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation

Blood - Tập 95 - Trang 3273-3279 - 2000
Jens Pedersen-Bjergaard1, Mette Klarskov Andersen1, Debes H. Christiansen1
1Section for Hematology/Oncology, Cytogenetic Laboratory; Department of Clinical Genetics, Juliane Marie Center, Rigshospitalet, Copenhagen, Denmark.

Tóm tắt

Abstract Therapy-related myelodysplasia (t-MDS) and acute myeloid leukemia (t-AML) after high-dose chemotherapy (HD-CT) and autologous stem cell transplantation (ASCT) for malignant diseases have become an important problem. The actuarial risk has varied, but has often been high if compared to the risk after conventional therapy. Prior chemotherapy with large cumulative doses of alkylating agents is the most important risk factor. In addition, patient age and previous radiotherapy, particularly the use of total body irradiation (TBI) in the preparative regimen for ASCT, have been identified as risk factors. In 3 studies, patients transplanted with CD34+ cells from peripheral blood after chemotherapy priming showed a higher risk of t-MDS or t-AML than patients transplanted with cells isolated from the bone marrow without priming. To what extent this higher risk relates to the prior therapy with a different contamination with preleukemic, hematopoietic precursors of the CD34+ cells obtained by the 2 methods, or is a direct result of chemotherapy priming, or of an increasing awareness of these complications, remains to be determined. The latent period from ASCT to t-MDS and t-AML has often been short, 12 months or less in 27% of the patients. Bone marrow pathology of early cases of t-MDS after ASCT has often been neither diagnostic nor prognostic, but most patients presented chromosome aberrations, primarily deletions or loss of the long arms of chromosomes 5 and 7. The prognosis was in general poor, although 17% with indolent t-MDS survived more than 18 months from diagnosis, and most of these presented a normal karyotype or a single chromosome aberration.

Tài liệu tham khảo

Stone, 1994, Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress?, Blood., 83, 3437, 10.1182/blood.V83.12.3437.3437 Deeg, 1998, Malignancies after hematopoietic stem cell transplantation: many questions, some answers., Blood., 91, 1833, 10.1182/blood.V91.6.1833 Wheeler, 1990, Cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study., J Clin Oncol., 8, 648, 10.1200/JCO.1990.8.4.648 Biermann, 1993, High dose chemotherapy followed by autologous hematopoietic rescue in Hogkin's disease: long term follow-up in 128 patients., Ann Oncol., 4, 767, 10.1093/oxfordjournals.annonc.a058662 Marolleau, 1993, Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas., J Clin Oncol., 11, 590, 10.1200/JCO.1993.11.3.590 Rohatiner, 1994, Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma., J Clin Oncol., 12, 1177, 10.1200/JCO.1994.12.6.1177 Roman-Unfer, 1995, Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer., Bone Marrow Transplant., 16, 163 Miller, 1994, Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy., Blood., 83, 3780, 10.1182/blood.V83.12.3780.3780 Bhatia, 1996, Malignant neoplasms following bone marrow transplantation., Blood., 87, 3633, 10.1182/blood.V87.9.3633.bloodjournal8793633 Traweek, 1994, Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma., Blood., 84, 957, 10.1182/blood.V84.3.957.957 Krishnan, 1998, Risk factors for development of therapy-related leukemia (t-MDS/t-AML) following autologous transplantation (ABMT) for lymphoma [abstract]., Blood., 92, 493a Darrington, 1994, Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenousleukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies., J Clin Oncol., 12, 2527, 10.1200/JCO.1994.12.12.2527 Stone, 1994, Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma., J Clin Oncol., 12, 2535, 10.1200/JCO.1994.12.12.2535 Friedberg, 1999, Outcome in patients with myelodyplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma., J Clin Oncol., 17, 3128, 10.1200/JCO.1999.17.10.3128 Wheeler, 1997, Low incidence of post-transplant myelodysplasia/acute leukemia (MDS/AML) in NHL patients autotransplanted after cyclophosphamide, carmustine and etoposide (CBV) [abstract]., Blood., 90, 385b Taylor, 1997, Low incidence of myelodysplastic syndrome following transplantation using autologous non-cryopreserved bone marrow., Leukemia., 11, 1650, 10.1038/sj.leu.2400795 Pedersen-Bjergaard, 1997, High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure., Leukemia., 11, 1654, 10.1038/sj.leu.2400809 André, 1998, Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease., Blood., 92, 1933 Harrison, 1999, High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML., Br J Cancer., 81, 476, 10.1038/sj.bjc.6690718 Milligan, 1999, Secondary leukemia and myelodysplasia after autografting for lymphoma: results from the EBMT., Br J Haematol., 106, 1020, 10.1046/j.1365-2141.1999.01627.x Govindarajan, 1996, Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma., Br J Haematol., 95, 349, 10.1046/j.1365-2141.1996.d01-1891.x Laughlin, 1998, Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant., J Clin Oncol., 16, 1008, 10.1200/JCO.1998.16.3.1008 Kollmannsberger, 1998, Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors., J Clin Oncol., 16, 3386, 10.1200/JCO.1998.16.10.3386 Valagussa, 1982, Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease., Blood., 59, 488, 10.1182/blood.V59.3.488.488 Boice, 1983, Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU)., N Engl J Med., 309, 1079, 10.1056/NEJM198311033091802 Greene, 1986, Melphalan may be a more potent leukemogen than cyclophosphamide., Ann Intern Med., 105, 360, 10.7326/0003-4819-105-3-360 Tucker, 1988, Risk of second cancers after treatment for Hodgkin's disease., N Engl J Med., 318, 76, 10.1056/NEJM198801143180203 Kaldor, 1990, Leukemia following chemotherapy for ovarian cancer., N Engl J Med., 322, 1, 10.1056/NEJM199001043220101 van Leeuwen, 1994, Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage., J Clin Oncol., 12, 1063, 10.1200/JCO.1994.12.5.1063 Pedersen-Bjergaard, 1987, Larsen SO, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease., Lancet., I, 83, 10.1016/S0140-6736(87)92744-9 O'Donnell, 1979, Acute nonlymphocytic leukemia and acute myeloproliferative syndrome following radiation therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: clinical studies., Cancer., 44, 1930, 10.1002/1097-0142(197911)44:5<1930::AID-CNCR2820440556>3.0.CO;2-E Travis, 1996, Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma., J Clin Oncol., 14, 565, 10.1200/JCO.1996.14.2.565 Perry, 1999, Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin's disease: equivalent survival outcome in a single-centre matched-pair analysis., Br J Haematol., 105, 280, 10.1111/j.1365-2141.1999.01280.x Carella, 1995, Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukaemia., Br J Haematol., 89, 535, 10.1111/j.1365-2141.1995.tb08360.x Carella, 1996, In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia., Br J Haematol., 95, 127, 10.1046/j.1365-2141.1996.7292351.x Abruzzese, 1999, Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation., Blood., 94, 1814 Roy, 1990, Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium., Blood., 75, 296, 10.1182/blood.V75.1.296.296 Rege, 1998, Secondary leukemia characterized by monosomy 7 occurring post-autologous stem cell transplantation for AML., Bone Marrow Transplant., 21, 853, 10.1038/sj.bmt.1701181 Bennett, 1976, Proposals for the classification of the acute leukemias: French-American-British (FAB) co-operative group., Br J Haematol., 33, 451, 10.1111/j.1365-2141.1976.tb03563.x Bennett, 1982, Proposals for the classification of the myelodysplastic syndromes., Br J Haematol., 51, 189, 10.1111/j.1365-2141.1982.tb08475.x Greenberg, 1997, International scoring system for evaluating prognosis in myelodysplastic syndromes., Blood., 89, 2079, 10.1182/blood.V89.6.2079 Wilson, 1997, Myelodysplastic syndrome occurring after autologous bone marrow transplantation for lymphoma: morphologic features., Am J Clin Pathol., 108, 369, 10.1093/ajcp/108.4.369 Amigo, 1999, Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS., Bone Marrow Transplant., 23, 997, 10.1038/sj.bmt.1701757 Sobecks, 1999, Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation., Bone Marrow Transplant., 23, 1161, 10.1038/sj.bmt.1701781 Le Beau, 1986, Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7., J Clin Oncol., 4, 325, 10.1200/JCO.1986.4.3.325 Johansson, 1991, Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL)., Eur J Haematol., 47, 17, 10.1111/j.1600-0609.1991.tb00556.x Pedersen-Bjergaard, 1995, Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia., Blood., 86, 3542, 10.1182/blood.V86.9.3542.bloodjournal8693542 Pui, 1989, Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia., N Engl J Med., 321, 136, 10.1056/NEJM198907203210302 Pedersen-Bjergaard, 1991, Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II., Blood., 78, 1147, 10.1182/blood.V78.4.1147.1147 Larson, 1992, Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia., Blood., 79, 1892, 10.1182/blood.V79.7.1892.1892 Pedersen-Bjergaard, 1998, Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors., J Clin Oncol., 16, 1897, 10.1200/JCO.1998.16.5.1897 Pedersen-Bjergaard, 1998, Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases., Genes Chromosomes Cancer., 23, 337, 10.1002/(SICI)1098-2264(199812)23:4<337::AID-GCC9>3.0.CO;2-L Imrie, 1998, New clonal karyotypic abnormalities acquired following autologous bone marrow transplantation for acute myeloid leukemia do not appear to confer an adverse prognosis., Bone Marrow Transplant., 21, 395, 10.1038/sj.bmt.1701105 Pedersen-Bjergaard, 1990, Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia., Blood., 76, 1083, 10.1182/blood.V76.6.1083.1083 Ballen, 1997, Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia., Bone Marrow Transplant., 20, 737, 10.1038/sj.bmt.1700971 Anderson, 1997, Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy., Blood., 89, 2578, 10.1182/blood.V89.7.2578 Chao, 1991, Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease., J Clin Oncol., 9, 1575, 10.1200/JCO.1991.9.9.1575 Gale, 1996, Demonstration of developing myelodysplasia/acute myeloid leukemia in haematologically normal patients after high-dose chemotherapy and autologous bone marrow transplantation using X-chromosome inactivation patterns., Br J Haematol., 93, 53, 10.1046/j.1365-2141.1996.4751014.x Mach-Pascual, 1998, Predictive value of clonality assays in patients with Non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study., Blood., 91, 4496, 10.1182/blood.V91.12.4496 Micallef, 2000, Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies., J Clin Oncol., 18, 947, 10.1200/JCO.2000.18.5.947 Yakoub-Agha, 2000, Allogenic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients—Report of the French Society of Bone Marrow Transplantation., J Clin Oncol., 18, 963, 10.1200/JCO.2000.18.5.963 Krishnan, 2000, Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors., Blood., 95, 1588, 10.1182/blood.V95.5.1588.005k38_1588_1593
Thông tin
Thông tin xuất bản

Blood

Tập 95

3273-3279

Thông tin tác giả